Stryker Co. (NYSE:SYK) Receives Average Rating of “Moderate Buy” from Analysts

Stryker Co. (NYSE:SYK) has received a consensus rating of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $340.67.

SYK has been the subject of several recent analyst reports. Citigroup upped their target price on shares of Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Royal Bank of Canada lifted their target price on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Evercore ISI boosted their price target on Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Finally, Roth Mkm upped their target price on shares of Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st.

Stryker Price Performance

Shares of Stryker stock opened at $335.61 on Tuesday. The stock’s fifty day moving average is $348.88 and its 200 day moving average is $315.16. Stryker has a one year low of $249.98 and a one year high of $361.41. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. The stock has a market cap of $127.69 billion, a P/E ratio of 40.68, a P/E/G ratio of 2.71 and a beta of 0.89.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter last year, the company earned $3.00 earnings per share. Sell-side analysts anticipate that Stryker will post 11.86 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is 38.79%.

Insider Buying and Selling

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the sale, the director now directly owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 212,109 shares of company stock valued at $72,845,768. Company insiders own 5.90% of the company’s stock.

Institutional Trading of Stryker

Several institutional investors and hedge funds have recently modified their holdings of SYK. Harbor Investment Advisory LLC grew its holdings in Stryker by 0.4% during the first quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock valued at $2,499,000 after purchasing an additional 31 shares during the period. Aspen Investment Management Inc increased its position in shares of Stryker by 0.7% in the 1st quarter. Aspen Investment Management Inc now owns 4,368 shares of the medical technology company’s stock valued at $1,563,000 after buying an additional 31 shares in the last quarter. Bremer Bank National Association lifted its holdings in Stryker by 4.0% during the fourth quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock worth $266,000 after acquiring an additional 34 shares in the last quarter. Simon Quick Advisors LLC grew its stake in Stryker by 3.0% in the fourth quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock valued at $347,000 after acquiring an additional 34 shares during the period. Finally, Consolidated Portfolio Review Corp increased its holdings in shares of Stryker by 3.6% in the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock worth $294,000 after acquiring an additional 34 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.